Back to search

The Open University

Combination treatments in <i>in vitro</i> and <i>in vivo</i> models between molecules reverting epigenetic gene silencing and DNA-interacting anticancer drugs

Abstract

dc:description.abstract

Epigenetic transcriptional gene silencing plays a fundamental role in cancer development and has been considered as a target for cancer therapy in the last few years, mainly due to its reversibility by small molecules. Among the several methylated genes investigated, glutathione-S-transferase (GST) P1, a protein belonging to cellular detoxification systems, has been shown to be extensively promoter-methylated in prostate cancer. My study therefore describes a new therapeutic approach against prostate cancer, based on the combination of demethylating agents and brostallicin, a DNA minor groove binding drug, which is activated in the cell by binding to glutathione, a reaction catalyzed by GST. <br></br><br></br>Among the demethylating molecules tested on the prostatic cancer cell line LNCaP in <i>in vitro</i> combinations with brostallicin, zebularine was able to increase brostallicin activity with little toxicity compared to the other tested demethylating drugs. <br></br><br></br>These <i>in vitro</i> results prompted the <i>in vivo</i> testing of zebularine with brostallicin on LNCaP cells transplanted in mice. Prolonged treatment with zebularine was able to significantly improve brostallicin antitumour activity compared to both drugs administrated as single agents. When GSTP1 expression was investigated in treated samples versus untreated controls, no protein re-expression was found and this was related to the unchanged levels of GSTP1 promoter methylation. In contrast, the demethylating effect of zebularine was clearly evident in the promoter of GSTM1 gene, which is also silenced by methylation in LNCaP cells. GSTM1 codes for a class of GST enzymes that has recently been found to be more active on brostallicin than GSTP1. <br></br><br></br>This indicates that the activation of brostallicin cytotoxicity in LNCaP cells by zebularine likely depends on enzymatic activation by GSTM1 rather than GSTP1 and strengthens the feasibility of this combination as a treatment for prostate cancer in the clinic, and as model for the therapy of other solid tumours.

Degree

thesis:*
Name dc:type.qualificationname
phd
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
The Open University
Year dc:date.issued
2008

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Sabatino, Maria Antonietta

Rights

Language dc:language
en

Chain of custody

source
Harvested from
The Open University
Base URL
oro.open.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Sabatino, Maria Antonietta. Combination treatments in <i>in vitro</i> and <i>in vivo</i> models between molecules reverting epigenetic gene silencing and DNA-interacting anticancer drugs. doctoral thesis, The Open University, 2008.